18+ · Research Use Only · Not for Human Consumption
The metabolic research stack: receptor-level and cell-level, layered.
Metabolic protocols increasingly combine an incretin agonist with a mitochondrial peptide. The reasoning behind the layers, and what each vial costs locally.
The receptor layer: incretin agonists
The top layer of metabolic research is receptor signaling. Incretin agonists act on the GLP-1, GIP, and in retatrutide's case glucagon receptors, the pathways behind the most heavily published metabolic results of the decade. Tirzepatide's SURMOUNT-1 trial (NEJM 2022) reported 22.5% mean weight reduction at 72 weeks. Retatrutide's Phase 2 (Jastreboff et al., NEJM 2023) reported 24.2% at 48 weeks, the strongest incretin readout published to date, with Phase 3 TRIUMPH ongoing through 2026.
In the catalogue, retatrutide 10mg anchors the stack at ₱2,790, or ₱2,510 on a first order. Tirzepatide 10mg lists at ₱2,500, ₱2,250 first order. Choosing between them is a question of research focus, unpacked in the retatrutide versus tirzepatide comparison.
The cellular layer: MOTS-c
Below receptor signaling sits cellular energy handling, and that is MOTS-c territory. MOTS-c is a short peptide encoded in mitochondrial DNA, studied in rodent models as an exercise mimetic through AMPK activation: the cell's energy-sensing pathway. Where an incretin changes what signals a cell receives, MOTS-c research asks how the cell's own energy machinery responds.
That is why metabolic protocols layer the two rather than choosing between them. They address different levels of the same system, and a study design can probe both without the compounds overlapping mechanistically. MOTS-c ships as a 20mg vial at ₱1,980, or ₱1,780 first order, and sells through quickly when batches land. The rodent evidence, including what it does not show, is reviewed in the MOTS-c deep dive.
Building the stack from local stock
To restate the framing: stacks describe how research protocols combine compounds, not personal-use guidance. Every compound here is supplied for laboratory research only and none is FDA approved for human use.
Practically, the stack is ordered in one WhatsApp chat. Both compounds are in stock and order together in one WhatsApp chat, dispatching same day across Metro Manila on verified orders placed before noon.
Supplied for laboratory research use only. Not for human consumption. Nothing on this page is medical advice.
Metabolic stack questions
What is a metabolic research stack?
In research protocols, it means combining an incretin receptor agonist like retatrutide or tirzepatide with a mitochondrial-level compound like MOTS-c inside one study design. The incretin works at the receptor and signaling level, MOTS-c at the cellular energy level.
Which incretin anchors the stack?
Retatrutide is the most requested anchor in the catalogue: a triple agonist that posted 24.2% mean weight reduction at 48 weeks in Phase 2. Tirzepatide, the dual agonist behind Mounjaro, is the alternative. Both are 10mg vials.
What does the stack cost?
Retatrutide 10mg is ₱2,790, or ₱2,510 first order. MOTS-c 20mg is ₱1,980, or ₱1,780 first order. Tirzepatide 10mg lists at ₱2,500, or ₱2,250 first order, also stock-dependent.
Are MOTS-c and tirzepatide available now?
Yes, both are in stock. Retatrutide 10mg is ₱2,510 on a first order and MOTS-c 20mg is ₱1,780, and both ship together in one insulated pack with same-day Metro Manila dispatch.